Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Apogee Enterprises
APOG
$888M
| $1.62M | ﹤0.01% |
44,629
+6,826
| +18% | +$258K |
|
3052
Bristow Group
VTOL
$1.38B
| $1.62M | ﹤0.01% |
44,361
-1,927
| -4% | -$72.5K |
|
3053
Porch Group
PRCH
$1.92B
| $1.62M | ﹤0.01% |
177,803
+41,732
| +31% | +$503K |
|
3054
Bilibili
BILI
$7.14B
| $1.62M | ﹤0.01% |
65,998
+5,917
| +10% | +$159K |
|
3055
Solid Power
SLDP
$545M
| $1.62M | ﹤0.01% |
381,605
+166,815
| +78% | +$921K |
|
3056
Northeast Bank
NBN
$1.16B
| $1.61M | ﹤0.01% |
15,536
+3,472
| +29% | +$324K |
|
3057
Dentsply Sirona
XRAY
$2.31B
| $1.61M | ﹤0.01% |
141,188
-107,085
| -43% | -$1.26M |
|
3058
Janus International
JBI
$686M
| $1.61M | ﹤0.01% |
246,575
+30,987
| +14% | +$241K |
|
|
SEZL
3059
Sezzle
SEZL
$4.37B
| $1.61M | ﹤0.01% |
25,353
+2,684
| +12% | +$183K |
|
3060
CALL
Blackrock
BLK
$183B
| $1.61M | ﹤0.01% |
1,500
-600
| -29% | -$656K |
|
3061
CorMedix
CRMD
$639M
| $1.6M | ﹤0.01% |
137,930
+7,399
| +6% | +$81.8K |
|
3062
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.6B
| $1.6M | ﹤0.01% |
29,677
-5,433
| -15% | -$294K |
|
3063
AdaptHealth
AHCO
$760M
| $1.59M | ﹤0.01% |
159,947
+16,451
| +11% | +$157K |
|
|
RAPP
3064
Rapport Therapeutics
RAPP
$2.27B
| $1.59M | ﹤0.01% |
52,480
+25,767
| +96% | +$713K |
|
|
JAMF
3065
DELISTED
Jamf
JAMF
| $1.59M | ﹤0.01% |
122,046
-49,644
| -29% | -$602K |
|
3066
FIGS
FIGS
$2.47B
| $1.59M | ﹤0.01% |
139,525
-12,402
| -8% | -$116K |
|
3067
Amerant Bancorp
AMTB
$1.14B
| $1.58M | ﹤0.01% |
81,103
+15,843
| +24% | +$295K |
|
3068
Covenant Logistics
CVLG
$880M
| $1.58M | ﹤0.01% |
71,732
+65
| +0.1% | +$1.36K |
|
3069
Astrana Health
ASTH
$1.87B
| $1.58M | ﹤0.01% |
63,639
+5,225
| +9% | +$139K |
|
3070
Southside Bancshares
SBSI
$984M
| $1.57M | ﹤0.01% |
51,590
+9,392
| +22% | +$275K |
|
3071
Sixth Street Specialty
TSLX
$1.82B
| $1.57M | ﹤0.01% |
72,066
-16,851
| -19% | -$368K |
|
3072
Gorman-Rupp
GRC
$2.11B
| $1.56M | ﹤0.01% |
32,758
+2,036
| +7% | +$94.8K |
|
|
CBL
3073
CBL Properties
CBL
$1.78B
| $1.56M | ﹤0.01% |
42,192
+6,815
| +19% | +$222K |
|
3074
PUT
BridgeBio Pharma
BBIO
$15.9B
| $1.56M | ﹤0.01% |
20,400
| – | – |
|
3075
American Express Global Business Travel
GBTG
$4.94B
| $1.56M | ﹤0.01% |
203,854
-163,671
| -45% | -$1.27M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.